Preclinical assessment of 90Y-labeled monoclonal antibody CO17-1A, a potential agent for radioimmunotherapy of colorectal carcinoma.
Monoclonal antibody CO17-1A was radiolabeled with 90Y using the cyclic DTPA anhydride technique and administered intravenously to athymic nude mice bearing SW 948 human colorectal carcinomas. The tumor specificity of 90Y-CO17-1A was improved by coadministration of 100 micrograms of the unlabeled antibody per animal and by purification using HPLC instead of column gel filtration chromatography. Absorbed radiation dose estimates for 90Y-CO17-1A were calculated. The radiation dose to the bone marrow will limit the amount of 90Y-CO17-1A that can be administered for cancer therapy.